News ArchivesRead News
Austrian Biotech Firm's Parkinson's Vaccine
Wednesday July 30, 2014
The Local - An Austrian company has developed a potentially viable vaccine for early-stage Parkinson's disease. The treatment, which is designed to slow or even stop progression of the disease, has undergone a Phase I clinical trial, from which data was released on Thursday in New York.
The treatment is based on a candidate vaccine known as PD01A, which lowers levels of alpha-synuclein. This is a brain protein which is believed to play an important role in maintaining a supply of synaptic vesicles in presynaptic terminals, as well as helping to regulate the release of dopamine, a type of neurotransmitter that is critical for controlling the start and stop of voluntary and involuntary movements.
The trial was conducted at the Confraternität Privatklinik Josefstadt in Vienna and involved up to 32 patients.
The preliminary results of the trial showed that the vaccine was well tolerated and safe, that it induced an immune response, and that the immune response appeared to be improving function.
"If you add all this together, I think we have the first evidence that would tell us that these findings are compatible with what we look for with disease modification," Achim Schneeberger, MD, chief medical officer of AFFiRiS, the Austrian pharmaceutical company developing the drug, told a press conference where the initial results were released.
AFFiRiS AG employs 100 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria where the vaccine was developed. In addition to its work on the Parkinson's vaccine, the company has been developing peptide vaccines for Alzheimer's disease and Atherosclerosis.
In part, the research was funded by the Michael J. Fox Foundation to the tune of $1.5 million (€1.12 million). The foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. Its founder, Michael J. Fox, is a well-known Canadian-American actor who is a high-profile victim of the disease.
(30 July 2014). The Local. Austrian Biotech Firm's Parkinson's Vaccine. http://www.thelocal.at/20140730/austrian-biotech-to-release-parkinsons-vaccine-data
Recent NewsJun 13 - Brain Cell Transplants Are Being Tested Once Again For Parkinson's
Jun 12 - Smell Test May Sniff Out Oncoming Parkinson's and Alzheimer's
Jun 8 - Smartphones Track Motor Function in Parkinson's Disease
Jun 8 - GKC Enrolls First Patient in Personal KinetiGraph Trial as Part of NPF’s Parkinson’s Outcomes Project
Jun 8 - Low-fat dairy intake may raise Parkinson's risk
Jun 6 - Patient Voices: Parkinson's Disease
Jun 1 - World-First Trials Have Been Launched to Treat Parkinson's And Blindness With Embryonic Stem Cells
May 24 - Survival Rates Differ Widely in Parkinson's, MSA, Lewy Bodies
May 22 - Discovery may offer hope to Parkinson's disease patients
May 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia
May 5 - Parkinson's in a dish: Researchers reproduce brain oscillations
May 5 - ‘Hunger Hormone’ Could Help Treat Parkinson’s Disease
May 3 - Antibiotic doxycycline may offer hope for treatment of Parkinson's disease
May 1 - Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness
Apr 28 - Does Parkinson’s disease begin in the gut?
Apr 28 - New empathy-creating digital device could be revolutionary for caregivers
Apr 24 - Treating Depression With Deep Brain Stimulation Works—Most of the Time
Apr 24 - Parkinson’s disease shows links to depression
Apr 21 - TOLEDO Trial: Apomorphine Infusions Reduce 'Off' Time in Parkinson's Disease
Apr 21 - New drug provides long-awaited breakthrough for Parkinson's psychosis